Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
NCT00887146 · View on ClinicalTrials.gov ↗
Study Summary
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma.
Conditions Studied
Interventions
- RADIATION radiotherapy
- DRUG concomitant temozolomide (TMZ)
- DRUG procarbazine
- DRUG adjuvant temozolomide (TMZ)
- DRUG CCNU
Study Locations (20)
California
- Kaiser Permanente-Anaheim — Anaheim
- Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn
- Mills-Peninsula Medical Center — Burlingame
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park — Cameron Park
- Community Cancer Institute — Clovis
- University Oncology Associates — Clovis
- UC San Diego Moores Cancer Center — La Jolla
- Kaiser Permanente Los Angeles Medical Center — Los Angeles
- Cedars Sinai Medical Center — Los Angeles
Alaska
- Anchorage Associates in Radiation Medicine — Anchorage
- Alaska Oncology and Hematology LLC — Anchorage
- Alaska Women's Cancer Care — Anchorage
- Anchorage Oncology Centre — Anchorage
- Katmai Oncology Group — Anchorage
- Providence Alaska Medical Center — Anchorage
Arizona
- Saint Joseph's Hospital and Medical Center — Phoenix
- Arizona Oncology-Deer Valley Center — Phoenix
- Arizona Oncology Services Foundation — Scottsdale
Alabama
- University of Alabama at Birmingham Cancer Center — Birmingham
- Providence Hospital — Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2009-09 |
| Est. Completion | 2029-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00887146
The ClinicalTrials.gov registry entry for NCT00887146 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 147 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 5 interventions — of which radiotherapy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00887146 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Alaska, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00887146 about?
NCT00887146 is a clinical study titled "Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma". Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and ...
What is the current status of trial NCT00887146?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 305 participants. The study started on 2009-09. Estimated completion is 2029-10-31.
What conditions does trial NCT00887146 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00887146?
The interventions under investigation include: radiotherapy (RADIATION), concomitant temozolomide (TMZ) (DRUG), procarbazine (DRUG), adjuvant temozolomide (TMZ) (DRUG), CCNU (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00887146?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 147 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00887146 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.